Intellectual Property India Publishes Patent Application for 'Cldn18.2/4-1bb Binding Protein And Medical Use Thereof' Filed by Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Shengdi Pharmaceutical Co. Ltd.

MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517058187 A) filed by Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Shengdi Pharmaceutical Co. Ltd., Jiangsu, China, on June 17, for 'cldn18.2/4-1bb binding protein and medical use thereof.'

Inventor(s) include Hu, Rongting; Guo, Ne; Li, Dan; Chen, Simeng; Lin, Yuan; and Liao, Cheng.

The application for the patent was published on July 4, under issue no. 27/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to a CLDN18.2/4-1BB binding protein and a medical use thereof. Specifically, the present disclosure relates to a CLDN18.2/4-1BB binding protein, a 4-1BB binding protein, a CD16A binding protein, methods for treating cancer by using same, and related pharmaceutical uses."

The patent application was internationally filed on Nov. 29, 2023, under International application No.PCT/CN2023/134972.

Disclaimer: Curated by HT Syndication.